Title:
OPTICALLY ACTIVE CROSSLINKED CYCLIC SECONDARY AMINE DERIVATIVE
Document Type and Number:
WIPO Patent Application WO/2019/189732
Kind Code:
A1
Abstract:
The present invention pertains to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, said compound inhibiting the binding of an MLL fusion protein, in which a typical fusion partner gene such as AF4 or AF9 inducing MLL leukemia is fused, to menin and thus exerting an antitumor effect. [In the formula: p represents 1 or 2; R1 represents -CF3, etc.; R2a, R2b, R3a and R3b represent a hydrogen atom, etc.; and X represents -C(=O)-, etc.]
Inventors:
KAMIOKA SEIJI (JP)
SHIMADA NAOAKI (JP)
HIROSE WATARU (JP)
BAN HITOSHI (JP)
YOKOYAMA AKIHIKO (JP)
SHIMADA NAOAKI (JP)
HIROSE WATARU (JP)
BAN HITOSHI (JP)
YOKOYAMA AKIHIKO (JP)
Application Number:
PCT/JP2019/013941
Publication Date:
October 03, 2019
Filing Date:
March 29, 2019
Export Citation:
Assignee:
SUMITOMO DAINIPPON PHARMA CO LTD (JP)
International Classes:
C07D519/00; A61K31/439; A61P35/00; A61P35/02
Domestic Patent References:
| WO2017112768A1 | 2017-06-29 |
Foreign References:
| JP2016512514A | 2016-04-28 | |||
| CN106831787A | 2017-06-13 |
Attorney, Agent or Firm:
YAMAO, Norihito et al. (JP)
Download PDF: